ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025 20:00 ET | Source: ORIC Pharmaceuticals Highly differentiated 1L…
Elekta showcases Evo, its AI-powered, online adaptive CT-Linac at the Association of Medical Physicists of India – National Congress 2025 (AMPICON) in Guwahati
Evo features high-definition image quality and online adaptive radiotherapy capabilities for treating…
ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025 01:00 ET | Source: ORIC Pharmaceuticals Systemic activity of…
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION Platform at the European Society of Medical Oncology Annual Congress
October 19, 2025 10:00 ET | Source: AVACTA GROUP PLC Median progression…
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
October 19, 2025 08:00 ET | Source: Replimune, Inc. WOBURN, Mass., Oct.…
At the World Congress of Neurology, WHO Outlines a Global Roadmap to Make Brain Health a Universal Reality
SEOUL, South Korea and LONDON, Oct. 15, 2025 /PRNewswire/ -- Neurological conditions…
ZTE hosts Global Summit & User Congress 2025 in Milan under the theme “Expanding Intelligence, Creating Possibilities”
MILAN, Oct. 9, 2025 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a…
Ariceum Therapeutics Data at the 2025 European Association of Nuclear Medicine Annual Congress Further Supports the Advancement of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer and Merkel Cell Carcinoma
October 09, 2025 02:00 ET | Source: Ariceum Therapeutics Oral presentation by…
Breakthrough Lectures to Headline the 2025 World Congress of Neurology in Seoul
SEOUL, South Korea, Oct. 8, 2025 /PRNewswire/ -- The World Federation of Neurology…
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders
– ARV-102 was well tolerated in clinical trials for both healthy volunteers…
